by Kazeem Olalekan MRPharmS
My long standing gripe about Packaging is still there (2). Why is the MHRA focusing too much attention on this? It seems trivial and well…not green!
Whilst I disagreed with the criticism of the MHRA by Mr Mel Braham (3), the editorial in the Lancet about lesson from the USA (4) may offer a way forward with regards to how the regulation of medical devices should change in the future. Professor Toft of Coventry University also identified that the EU regulatory framework is not fit for purpose (5). The MHRA according to professor Toft, does not have the power to do the things they have to do pro-actively. The comments by the good professor is worth listening to.
There are other suggestion on the configuration of the MHRA that is definitely worth listening to: They are joint comments by my professional body and other pharmacy organisations (6). They revolve around the following:
- Cost of implementing a single set of regulation
- Future guidance
- Removing prepared medicines
- Abolishing fluted bottles
- Statutory warning for medicines
- Obsolete exemptions
- Universities and research institutions
- Patient group directions
- Optimisation of Medicines
The statement is comprehensive and include a number of other changes which Royal Pharmaceutical Society will like to see.
So there is no better time than the present for the MHRA to intensify its effort to address all of these issues. I am sure the organisation is doing just that.